Gallium maltolate treatment for recurrent glioblastoma
Part of Cancer clinical trials.
This trial gives access to gallium maltolate, an oral investigational drug, for people whose glioblastoma has returned and who have no other good options. The goal is to see if it can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of brain cancer called glioblastoma that has come back or stopped responding to treatment.
- You must be able to swallow pills.
- You cannot be taking iron supplements or iron chelators.
- You cannot be pregnant or breastfeeding and must use effective birth control during treatment and for 4 months after.
- You must agree to be in a separate outcomes registry and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called gallium maltolate for people whose glioblastoma (a type of brain cancer) has returned after standard treatment. The drug is given by mouth and may help slow tumor growth.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This study tests a light-activated therapy (radiodynamic therapy) using a special medicine to help treat a brain tumor that has come back after prior treatment. It may be offered after doctors decide you need further radiation for your recurrence.
This study tests an experimental treatment given after the standard first treatment (chemotherapy and radiation) for newly diagnosed glioblastoma, a type of brain cancer. It aims to see if this extra treatment helps keep the cancer from coming back.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
This trial tests a new drug called CM93 that targets a specific change (EGFR) in recurrent glioblastoma, a type of brain cancer. The goal is to see if it can slow or stop tumor growth and to find the best dose.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.